LIGAND Pharmaceuticals director Zimmermann Martine sold 1,200 shares at $285 per share. The transaction represented about 23.5% of the director’s prior holding, while the reported post-sale balance was 3,897 shares, giving investors the disclosed scale and remaining ownership position.
Key Highlights
- The transaction was recorded on 10 September 2026 under code S, denoting an open-market sale.
- Zimmermann Martine’s reported holding stood at 3,897 shares after the transaction.
- Zimmermann Martine sold 1,200 LIGAND Pharmaceuticals shares at $285 per share on 10 September 2026.
LIGAND PHARMACEUTICALS INC (NASDAQ: LGND) director Zimmermann Martine sold 1,200 shares at $285 per share.
Transaction Coded as Open-Market Sale
The transaction date was 10 September 2026. The reported sale relates directly to Zimmermann Martine’s holdings in LIGAND.
Director’s Post-Transaction Holding
Zimmermann Martine’s reported position after the transaction was 3,897 shares. The sale represented about 23.5% of the director’s prior shareholding. The two figures use different reference points: 3,897 shares describes the balance after the trade, while 23.5% measures the transaction against the earlier holding.
FAQs
Q: How many LIGAND Pharmaceuticals shares did Zimmermann Martine sell?
A: Zimmermann Martine sold 1,200 LIGAND Pharmaceuticals shares at $285 per share on 10 September 2026. The director’s reported holding afterward was 3,897 shares.
Q: What was the impact of the LIGAND insider sale?
A: The open-market sale represented about 23.5% of director Zimmermann Martine’s prior shareholding. After selling 1,200 LIGAND shares at $285 per share, the reported position was 3,897 shares.
Q: What does transaction code S mean for LGND stock?
A: Code S identifies an open-market sale in transaction reporting. Zimmermann Martine was identified as a director of LIGAND Pharmaceuticals INC.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.